OncoMatch/Colorectal Cancer (CRC)/EGFR
Colorectal Cancer (CRC)EGFR Clinical Trials
EGFR is the target of cetuximab and panitumumab, anti-EGFR monoclonal antibodies approved as standard of care for RAS/BRAF wild-type metastatic CRC. EGFR overexpression by IHC is common in CRC but less predictive than RAS/BRAF mutational status. Trials explore novel anti-EGFR antibodies, bispecific constructs, antibody-drug conjugates targeting EGFR, and strategies to restore sensitivity after acquired EGFR-pathway resistance.
Top recruiting EGFR Colorectal Cancer (CRC) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC
Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)
University of Saskatchewan
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Betta Pharmaceuticals Co., Ltd.
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
More EGFR Colorectal Cancer (CRC) trials
1 international trial (no US sites)
Browse other molecular targets with active Colorectal Cancer (CRC) trials.